Skip to main content
. 2015 Feb 9;34(42):5395–5405. doi: 10.1038/onc.2014.468

Figure 7.

Figure 7

HER2 cooperates with HACE1 allowing full malignant transformation. (a) In vivo tumor formation of MCF12A shHACE1 (1 and 2), MCF12A shNSC, MCF12A-HER2 shHACE1 (1 and 2) and MCF12A-HER2 shNSC cells. Cells were injected into NOD/SCID mice and allowed to grow for 30 weeks; n=6 per group. (b) Time course of In vivo tumor formation of MCF12A-HER2 shHACE1 (1 and 2) and MCF12A-HER2 shNSC cells. Cells were injected into NOD/SCID mice and allowed to grow for 20 weeks; n=10 per group. (c) Western blot analysis of MCF12A-HER2 shNSC and shHACE1 cell lines and primary tumors (d) MCF12A-HER2 shHACE1 tumor volumes from mice treated with intraperitoneal injections of 30 mg/kg EHT1864 or vehicle. Graphs show mean±s.e.m. of tumor volume at indicated days. n=4 or 5 mice per group. (d) Graph shows tumor weight after 21 days of vehicle or EHT1864 treatment of MCF12A-HER2 shHACE1 tumors (****P<0.00001 between groups, Student's t-test). Graphs show mean±s.e.m. of tumor weight; n=4 or 5 mice per group.